Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17.

Gemma A Figtree^{1

2}, Karin Rådholm^{2

3}, Terrance D Barrett⁴, Vlado Perkovic², Kenneth W Mahaffey⁵, Dick de Zeeuw⁶, Greg Fulcher¹, David R Matthews⁷, Wayne Shaw⁴, Bruce Neal^{2

8

9}

¹ Kolling Institute, Royal North Shore Hospital and University of Sydney, Australia (G.A.F., G.F.).
² The George Institute for Global Health, University of New South Wales, Sydney, Australia (G.A.F., K.R., V.P., B.N.).
³ Division of Community Medicine, Primary Care, Department of Medicine and Health Sciences, Faculty of Health Sciences, Linköping University, Department of Local Care West, County Council of Östergötland, Sweden (K.R.).
⁴ Janssen Research & Development, LLC, Raritan, NJ (T.D.B., W.S.).
⁵ Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).
⁶ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (D.d.Z.).
⁷ Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, United Kingdom (D.R.M.).
⁸ Faculty of Medicine, University of New South Wales, Sydney, Australia (B.N.).
⁹ Imperial College London, UK (B.N.).

No abstract available

Keywords: SGLT2 inhibitor; canagliflozin; heart failure; randomized trial; type 2 diabetes mellitus.

Publication types